Reliability note

Titles and AI summaries are unofficial English monitoring aids, not legal advice or official translations. Each link opens the original Japanese official source, which remains authoritative.

Emergency order suspends specified regenerative medicine at ICVS Tokyo Clinic

再生医療等の安全性の確保等に関する法律に基づく緊急命令について

Published: 2026-11-19 · Source: Ministry of Health, Labour and Welfare (MHLW) · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Low · First detected by this dashboard: 2026-11-20

View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard

AI summary

Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.

Summary

On 2026-11-19, the Ministry of Health, Labour and Welfare announced an emergency order under Article 22 of the Act on the Safety of Regenerative Medicine (Act No. 85 of 2013) against Medical Corporation ICVS Tokyo Clinic in Chiyoda City, Tokyo. The order required temporary suspension, among other measures, of regenerative medicine using dendritic cells and activated lymphocytes for advanced cancer. An investigation confirmed multiple serious illnesses or other serious events suspected of being related to that treatment; the ministry stated that reports required under Article 18 had not been submitted as of the announcement. The causes remained unidentified, and the ministry stated that it would investigate the circumstances and causes.

Business Impact

The order may affect Medical Corporation ICVS Tokyo Clinic's provision of the specified advanced-cancer treatment and patients receiving it. Other regenerative-medicine providers may find the case relevant to reviewing serious-event reporting under Article 18, although the announced order targets this clinic.

Recommended Action

The clinic and affected patients could review the order's precise suspension scope and any additional measures, which are not fully set out in the excerpt. Regenerative-medicine providers could review how their serious-event reporting procedures address Article 18.